# Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-plus-cetuximab-in-patients-with-recurrent-or-metastatic-head-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Assuntina G. Sacco,Ruifeng Chen,Francis P. Worden,Deborah Jean Lee Wong,Douglas R. Adkins,Paul Swiecicki,Wanxing Chai‐Ho,Peter Oppelt,Debanjali Ghosh,Julie Bykowski,Alfredo Molinolo,Emily Pittman,Mónica V. Estrada,Kathryn A. Gold,Gregory A. Daniels,Scott M. Lippman,Amanda Natsuhara,Karen Messer,Ezra E.W. Cohen |
| Citations | 262 |
| DOI | 10.1016/s1470-2045(21)00136-4 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/12140401 |
| OpenAlex ID | https://openalex.org/W3160114067 |
| PMID | 33989559 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Kathryn A. Gold](https://scholariq.org/researchers/kathryn-a-gold/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

## Paper topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.